Alkermes plc. Cash and Cash Equivalents, Period Increase (Decrease)
Alkermes plc. (ALKS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$4.79 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-26.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-04-26
- Alkermes plc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$4.79M.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $26.17M.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $7.02M, a 20.96% increase year-over-year.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$23.20M.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $4.92M, a 6.66% decline from fiscal 2016.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $5.27M.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$42.95M, a 176.02% decline from fiscal 2014.
- Alkermes plc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $56.50M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$4.79M 10-Q · filed 2018-04-26 | $21.38M derived: sum of 2 quarters · filed 2018-04-26 | $28.40M derived: sum of 3 quarters · filed 2018-04-26 | $5.20M derived: sum of 4 quarters · filed 2018-04-26 |
| 2017-12-31 | $26.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $33.19M derived: sum of 2 quarters · filed 2018-02-16 | $9.99M derived: sum of 3 quarters · filed 2018-02-16 | $4.92M 10-K · filed 2018-02-16 |
| 2017-09-30 | $7.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | -$16.18M derived: sum of 2 quarters · filed 2017-10-26 | -$21.25M 10-Q · filed 2017-10-26 | -$37.12M derived: sum of 4 quarters · filed 2018-04-26 |
| 2017-06-30 | -$23.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | -$28.27M 10-Q · filed 2017-07-27 | -$44.13M derived: sum of 3 quarters · filed 2018-04-26 | -$38.33M derived: sum of 4 quarters · filed 2018-04-26 |
| 2017-03-31 | -$5.07M 10-Q · filed 2018-04-26 | -$20.93M derived: sum of 2 quarters · filed 2018-04-26 | -$15.13M derived: sum of 3 quarters · filed 2018-04-26 | -$18.67M derived: sum of 4 quarters · filed 2018-04-26 |
| 2016-12-31 | -$15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$10.06M derived: sum of 2 quarters · filed 2018-02-16 | -$13.60M derived: sum of 3 quarters · filed 2018-02-16 | $5.27M 10-K · filed 2018-02-16 |
| 2016-09-30 | $5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $2.26M derived: sum of 2 quarters · filed 2017-10-26 | $21.13M 10-Q · filed 2017-10-26 | -$20.10M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $15.33M 10-Q · filed 2017-07-27 | -$25.90M derived: sum of 3 quarters · filed 2018-02-16 | -$455.00K derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $18.87M 10-Q · filed 2017-04-27 | -$22.36M derived: sum of 2 quarters · filed 2018-02-16 | $3.08M derived: sum of 3 quarters · filed 2018-02-16 | -$9.34M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$41.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$15.78M derived: sum of 2 quarters · filed 2018-02-16 | -$28.20M derived: sum of 3 quarters · filed 2018-02-16 | -$42.95M 10-K · filed 2018-02-16 |
| 2015-09-30 | $25.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $13.03M derived: sum of 2 quarters · filed 2016-11-02 | -$1.72M 10-Q · filed 2016-11-02 | $86.16M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$12.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$27.17M 10-Q · filed 2016-07-28 | $60.71M derived: sum of 3 quarters · filed 2017-02-17 | $8.57M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$14.75M 10-Q · filed 2016-04-28 | $73.13M derived: sum of 2 quarters · filed 2017-02-17 | $20.99M derived: sum of 3 quarters · filed 2017-02-17 | |
| 2014-12-31 | $87.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $35.74M derived: sum of 2 quarters · filed 2017-02-17 | $56.50M 10-K · filed 2017-02-17 | |
| 2014-09-30 | -$52.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | -$31.38M 10-Q · filed 2015-10-29 | ||
| 2014-06-30 | $20.76M 10-Q · filed 2015-07-30 | |||
| 2013-12-31 | $70.60M 10-K · filed 2016-02-25 | |||
| 2012-03-31 | -$1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-18 | -$5.64M derived: sum of 2 quarters · filed 2012-05-18 | $45.21M 10-K · filed 2012-05-18 | |
| 2011-12-31 | -$3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $46.94M 10-Q · filed 2012-02-02 | ||
| 2011-09-30 | $50.84M 10-Q · filed 2011-11-03 | |||
| 2011-03-31 | -$468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-18 | $1.14M derived: sum of 2 quarters · filed 2012-05-18 | -$40.93M 10-K · filed 2012-05-18 | |
| 2010-12-31 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | -$40.46M 10-Q · filed 2012-02-02 | ||
| 2010-09-30 | -$42.07M 10-Q · filed 2011-11-03 | |||
| 2010-03-31 | -$7.57M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |